MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

66.76
+1.39
+2.13%
After Hours: 66.76 0 0.00% 17:20 04/20 EDT
OPEN
64.80
PREV CLOSE
65.37
HIGH
66.85
LOW
64.63
VOLUME
719.94K
TURNOVER
--
52 WEEK HIGH
90.19
52 WEEK LOW
44.79
MARKET CAP
4.03B
P/E (TTM)
-9.0360
1D
5D
1M
3M
1Y
5Y
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
Business Wire · 1d ago
Arena Pharmaceuticals To Present Data From Phase 2b ADVISE Trial During Late-Breaking Research Session At American Academy Of Dermatology Virtual Meeting Experience
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P)
Benzinga · 1d ago
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
---Live Q&A session with presenter to be held on Saturday, April 24, 2021 at 3:00 PM ET
BusinessWire · 1d ago
Global Sleep Wake Disorder Market By Type, By Application, By Segmentation, By Region, and By Country 2021
Apr 19, 2021 (Heraldkeepers) -- The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size...
Heraldkeepers · 1d ago
Anti-Obesity Prescription Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
pune, India, Mon, 19 Apr 2021 01:48:54 / Comserve Inc. / -- The global Anti-Obesity Prescription market is segmented by company, region (country), by Type,...
Comserve · 1d ago
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new...
BusinessWire - BZX · 4d ago
Anti Obesity Drugs Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027
Market Stats News · 4d ago
Canine Weight Loss Drugs Market Industry Analysis, Market Size, Trends, Share and Forecast 2027
Apr 16, 2021 (Market Insight Reports) -- The report on Canine Weight Loss Drugs provides the clients with an in-depth analysis of market share, market size,...
Market Insight Reports · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARNA. Analyze the recent business situations of Arena Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARNA stock price target is 97.23 with a high estimate of 120.00 and a low estimate of 76.00.
EPS
Institutional Holdings
Institutions: 378
Institutional Holdings: 57.52M
% Owned: 95.34%
Shares Outstanding: 60.33M
TypeInstitutionsShares
Increased
87
6.73M
New
35
2.05M
Decreased
94
3.96M
Sold Out
32
3.61M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Non-Executive Chairman/Independent Director
Garry Neil
President/Chief Executive Officer/Director
Amit Munshi
Chief Financial Officer/Executive Vice President
Laurie Stelzer
Executive Vice President/General Counsel/Secretary
Joan Schmidt
Executive Vice President
Vincent Aurentz
Executive Vice President
Robert Lisicki
Senior Vice President
Paul Streck
Director
Katharine Knobil
Director
Nawal Ouzren
Independent Director
Jayson Dallas
Independent Director
Oliver Fetzer
Independent Director
Kieran Gallahue
Independent Director
Jennifer Jarrett
Independent Director
Manmeet Soni
Independent Director
Randall Woods
No Data
About ARNA
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARNA stock methods without spending real money on the virtual paper trading platform.